S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
Log in
NASDAQ:FGEN

FibroGen Stock Forecast, Price & News

$42.60
-3.01 (-6.60 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$42.42
Now: $42.60▼
$46.36
50-Day Range
$40.97
MA: $44.11▼
$48.97
52-Week Range
$22.65
Now: $42.60▼
$51.56
Volume1.08 million shs
Average Volume693,954 shs
Market Capitalization$3.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Read More
FibroGen logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.49 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FGEN
Previous Symbol
CUSIPN/A
CIK921299
Webwww.fibrogen.com
Phone415-978-1200
Employees531

Debt

Debt-to-Equity Ratio0.08
Current Ratio9.37
Quick Ratio9.26

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$256.58 million
Price / Sales15.00
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.14 per share
Price / Book6.94

Profitability

EPS (Most Recent Fiscal Year)($0.89)
Net Income$-76,970,000.00
Net Margins-287.01%
Return on Equity-60.97%
Return on Assets-36.79%

Miscellaneous

Outstanding Shares90,355,000
Market Cap$3.85 billion
Next Earnings Date11/9/2020 (Estimated)
OptionableOptionable
$42.60
-3.01 (-6.60 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











FibroGen (NASDAQ:FGEN) Frequently Asked Questions

How has FibroGen's stock price been impacted by Coronavirus (COVID-19)?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FGEN shares have increased by 20.3% and is now trading at $42.60.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of FibroGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for FibroGen.

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for FibroGen.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.31. The biopharmaceutical company earned $42.90 million during the quarter, compared to analysts' expectations of $48.29 million. FibroGen had a negative net margin of 287.01% and a negative return on equity of 60.97%. The firm's revenue was down 77.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 earnings per share.
View FibroGen's earnings history.

What price target have analysts set for FGEN?

5 Wall Street analysts have issued twelve-month target prices for FibroGen's stock. Their forecasts range from $40.00 to $90.00. On average, they expect FibroGen's share price to reach $59.60 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts' price targets for FibroGen.

Are investors shorting FibroGen?

FibroGen saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,910,000 shares, an increase of 16.1% from the August 31st total of 5,950,000 shares. Based on an average trading volume of 657,000 shares, the short-interest ratio is presently 10.5 days. Currently, 8.4% of the shares of the stock are sold short.
View FibroGen's Short Interest.

Who are some of FibroGen's key competitors?

Some companies that are related to FibroGen include Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Elanco Animal Health (ELAN), Myokardia (MYOK), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), CureVac B.V. (CVAC), Ascendis Pharma A/S (ASND), Galapagos (GLPG), Jazz Pharmaceuticals (JAZZ), Mylan (MYL) and Mirati Therapeutics (MRTX).
View all competitors.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Mr. James A. Schoeneck, Chairman (Age 62, Pay $751.63k)
  • Mr. Pat Cotroneo, Chief Financial Officer (Age 56, Pay $773.57k)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 58, Pay $926.21k)
  • Dr. Elias Kouchakji, Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance (Age 64, Pay $863.19k)
  • Ms. Christine L. Chung, Sr. VP of China Operations (Age 52, Pay $701.09k)

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.29%), Candriam Luxembourg S.C.A. (0.28%), BHK Investment Advisors LLC (0.04%), Envestnet Asset Management Inc. (0.03%), Polianta Ltd (0.03%) and Dowling & Yahnke LLC (0.01%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen.

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., and BHK Investment Advisors LLC. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen.

Which institutional investors are buying FibroGen stock?

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Polianta Ltd, Dowling & Yahnke LLC, Envestnet Asset Management Inc., Pacer Advisors Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $42.60.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.85 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 531 workers across the globe.

What is FibroGen's official website?

The official website for FibroGen is www.fibrogen.com.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.